ConductScience.org, home

Paper24639005

Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events.

Costabel U and 13 others. Adv Ther, 2014. Cited by 107 papers, by iCite.

Cite this record

ConductScience Library. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Papers, record 24639005. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24639005

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events.
PubMed
Journal
Adv Ther
PubMed
Year
2014
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
107
iCite
Relative citation ratio, by iCite
4.05
iCite
Revised in PubMed
2022-04-09
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Costabel UUlrich
2Bendstrup EElisabeth
3Cottin VVincent
4Dewint PPieter
5Egan JJJim J J
6Ferguson JJames
7Groves RRichard
8Hellström PMPer M
9Kreuter MMichael
10Maher TMToby M
11Molina-Molina MMaria
12Nordlind KKlas
13Sarafidis AAlexandre
14Vancheri CCarlo

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Drug-Related Side Effects and Adverse ReactionsMajor topic
Idiopathic Pulmonary FibrosisMajor topic
PyridonesMajor topic
Tumor Necrosis Factor-alphaMajor topic
Anti-Inflammatory Agents, Non-Steroidal
Disease Management
Disease-Free Survival
Humans
Respiratory Function Tests

Source PubMed

Download CSV of topics

References30

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118387510Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro.Int Immunopharmacol2008https://conductscience.org/library/papers/18387510PubMed
211923553Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland.Thorax2002https://conductscience.org/library/papers/11923553PubMed
315665326Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.Am J Respir Crit Care Med2005https://conductscience.org/library/papers/15665326PubMed
416844727Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK.Thorax2006https://conductscience.org/library/papers/16844727PubMed
517585107Acute exacerbations of idiopathic pulmonary fibrosis.Am J Respir Crit Care Med2007https://conductscience.org/library/papers/17585107PubMed
620935110Clinical course and prediction of survival in idiopathic pulmonary fibrosis.Am J Respir Crit Care Med2011https://conductscience.org/library/papers/20935110PubMed
719328861Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults.Pulm Pharmacol Ther2009https://conductscience.org/library/papers/19328861PubMed
820050822Pirfenidone: an anti-fibrotic therapy for progressive kidney disease.Expert Opin Investig Drugs2010https://conductscience.org/library/papers/20050822PubMed
923204124Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature.Eur Respir Rev2012https://conductscience.org/library/papers/23204124PubMed
1021571362Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.Lancet2011https://conductscience.org/library/papers/21571362PubMed
1121471066An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.Am J Respir Crit Care Med2011https://conductscience.org/library/papers/21471066PubMed
1212098599Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock.Eur J Pharmacol2002https://conductscience.org/library/papers/12098599PubMed
1319996196Pirfenidone in idiopathic pulmonary fibrosis.Eur Respir J2010https://conductscience.org/library/papers/19996196PubMed
1419345567Epidemiology of interstitial lung diseases in Greece.Respir Med2009https://conductscience.org/library/papers/19345567PubMed
1518093617Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts.Life Sci2008https://conductscience.org/library/papers/18093617PubMed
1622798316Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials.Am J Respir Crit Care Med2012https://conductscience.org/library/papers/22798316PubMed
1723056564Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials.PLoS One2012https://conductscience.org/library/papers/23056564PubMed
1821525528The rising incidence of idiopathic pulmonary fibrosis in the U.K.Thorax2011https://conductscience.org/library/papers/21525528PubMed
1921632796Antifibrotic activities of pirfenidone in animal models.Eur Respir Rev2011https://conductscience.org/library/papers/21632796PubMed
2012693805Incidence and prevalence of cryptogenic fibrosing alveolitis in a Norwegian community.Respir Med2003https://conductscience.org/library/papers/12693805PubMed

See all 30 referencesDownload CSV of references

Cited by66

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 107 citations.

PMIDTitleJournalYearIn PapersSource
42797420Development and Evaluation of a Novel Inhalable Liposomal Powder Co-Encapsulating ASSNAC and Pirfenidone via Spray Freeze-Drying for Targeted Pulmonary Fibrosis Therapy.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42797420PubMed
42794585A Comparative Assessment of the Antifibrotic Effect of Nintedanib Administered via a Medicated Diet or Oral Gavage in a Rat Model of Bleomycin-Induced Pulmonary Fibrosis.Int J Mol Sci2026https://conductscience.org/library/papers/42794585PubMed
42760377Gastrointestinal and skin safety evaluation of pirfenidone versus nintedanib: an analysis of real-world pharmacovigilance and randomized controlled trials.Naunyn Schmiedebergs Arch Pharmacol2026https://conductscience.org/library/papers/42760377PubMed
42563128Pharmacokinetics and Safety of Nerandomilast in Healthy Volunteers.Eur J Drug Metab Pharmacokinet2026https://conductscience.org/library/papers/42563128PubMed
41756284Yizong Tongluo formula attenuates idiopathic pulmonary fibrosis and inflammatory injury by inhibiting HIF-1α/LSH/SCD1-mediated ferroptosis.Front Immunol2026https://conductscience.org/library/papers/41756284PubMed
40843770Pirfenidone in Skin Fibrosis and Scarring: From Bench Insights to Clinical Data.Med Sci (Basel)2025https://conductscience.org/library/papers/40843770PubMed
40402087Noninvasive Evaluation of Prolonged-Release Pirfenidone in Compensated Liver Cirrhosis. ODISEA Study, a Randomised Trial.Liver Int2025https://conductscience.org/library/papers/40402087PubMed
40356972
Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases.
Front Pharmacol2025https://conductscience.org/library/papers/40356972PubMed
39459489Exploring the Role of Hemogram-Derived Ratios and Liver Fibrosis Scores in Pulmonary Fibrosis.Medicina (Kaunas)2024https://conductscience.org/library/papers/39459489PubMed
38967367Pirfenidone use in fibrotic diseases: What do we know so far?Immun Inflamm Dis2024https://conductscience.org/library/papers/38967367PubMed
37892651Factors Affecting Best-Tolerated Dose of Pirfenidone in Patients with Fibrosing Interstitial Lung Disease.J Clin Med2023https://conductscience.org/library/papers/37892651PubMed
37853864A Case of Pirfenidone-Induced Photosensitive Drug Eruption.Ann Dermatol2023https://conductscience.org/library/papers/37853864PubMed
36735694Factors associated with dose reduction of pirfenidone in patients with idiopathic pulmonary fibrosis: A study based on real-world clinical data.PLoS One2023https://conductscience.org/library/papers/36735694PubMed
36703754Clinical outcomes of dose modification during pirfenidone treatment for IPF: A nationwide post-marketing surveillance study.Front Pharmacol2022https://conductscience.org/library/papers/36703754PubMed
36674976Antifibrotic Effects of Caffeine, Curcumin and Pirfenidone in Primary Human Keratocytes.Int J Mol Sci2023https://conductscience.org/library/papers/36674976PubMed
36551989Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience.Biomedicines2022https://conductscience.org/library/papers/36551989PubMed
35996614Double Lung Transplantation for Idiopathic Pulmonary Fibrosis in a Patient with a History of Liver Transplantation and Prolonged Journey for Disease-Specific Antifibrotic Therapy.Case Rep Pulmonol2022https://conductscience.org/library/papers/35996614PubMed
35923422Electronically monitored medication adherence in idiopathic pulmonary fibrosis: prevalence, predictors and outcomes.ERJ Open Res2022https://conductscience.org/library/papers/35923422PubMed
35721111Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis.Front Pharmacol2022https://conductscience.org/library/papers/35721111PubMed
35568881Behavioural and psychological patterns of patients with idiopathic pulmonary fibrosis: a prospective study.Respir Res2022https://conductscience.org/library/papers/35568881PubMed

See all 66 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
TGFB17040PubTator's text mininghttps://conductscience.org/library/genes/7040NCBI Gene
TNF7124PubTator's text mininghttps://conductscience.org/library/genes/7124NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/24639005

GET https://conductscience.org/api/papers/v1/24639005/references?page=2